



Thoughtful Discussion on Article “Antimicrobial Peptide Cec4 Eradicates Multidrug-Resistant *Acinetobacter baumannii* in vitro and in vivo” [Letter]

Syarif Hidayat , Rina Isnawati, Novaria Sari Dewi Panjaitan 

Center for Biomedical Research, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong Science Center, Cibinong, West Java, Indonesia

Correspondence: Novaria Sari Dewi Panjaitan, Center for Biomedical Research, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong Science Center, Jl. Raya Bogor No. 490, Cibinong – Bogor Km. 46, Cibinong, West Java, Indonesia, Email nova014@brin.go.id

Dear editor

The works performed by Peng et al were much appreciated, as the effects of Cec4 on bacterial membrane permeability, membrane potential, and the production of bacterial reactive oxygen species were well-explored.¹ Based on the previous study, 41 amino acids-antimicrobial peptide Cec4 had been reported to be effective against the in vitro growth of *A. baumannii* ATCC19606 reference strain with a minimum inhibitory concentration (MIC) of 4 µg/mL which even quantitatively inhibits 50% formation of bacterial biofilm formed by *A. baumannii* ATCC19606 and carbapenem resistant *A. baumannii* clinical isolates.² The results reported in their recently published study were obviously promising. Furthermore, results regarding the *A. baumannii* bacterial load in *C. elegans* showed that the bacterial count in the nematodes was significantly lower compared under the treatment with Cec4 compared to the control group. This data showed the effectiveness of Cec4 antimicrobial peptides. However, after reading and reviewing this study in detail, a few suggestions for improving future studies in the field are provided here.

The control used in the experimental work designed to unravel the bactericidal effects of peptide Cec4 exerted through its binding ability to the bacterial cell membrane was not clearly explained. If the control used was the buffer system of the experiment, we advise that additional positive and negative controls be included in any future study.³ In addition, since a growing body of evidence suggests that potential antimicrobial peptides not only directly kill pathogens, but may also modulate and even bridge innate and adaptive immune responses,^{4,5} detailed information regarding immune response and essential survival protein levels of the cells under antimicrobial peptide treatment are highly suggested to be revealed together with the in vitro toxicity assay. Regardless, the works performed by the authors were appreciated since the detailed mechanisms of Cec4 antimicrobial activity started to be unraveled by proving that bacterial cell membrane was disrupted by Cec4 peptide and a higher level of ROS production in *A. baumannii* ATCC19606. A suggestion of exploring the specific protein or site targeted by the Cec4 peptide could be considered in future studies in this field.

Acknowledgments

We would like to acknowledge Peng et al, as the authors of the discussed study for their great works. The authors also would like to convey gratitude and acknowledge Dr. Sunarno and all researchers in the Center for Biomedical Research BRIN for the support.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising, or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure

All authors stated that there is no conflict of interest related to the work, authors, and affiliation of the discussed study.

References

1. Peng J, Wang Y, Wu Z, et al. Antimicrobial peptide Cec4 eradicates multidrug-resistant *Acinetobacter baumannii* in vitro and in vivo. *Drug Des Devel Ther.* 2023;17:977–992. doi:10.2147/DDDT.S405579
2. Liu W, Wu Z, Mao C, et al. Antimicrobial peptide Cec4 eradicates the bacteria of clinical carbapenem-resistant *Acinetobacter baumannii* biofilm. *Front Microbiol.* 2020;11:1–13. doi:10.3389/fmicb.2020.01532
3. Matsuzaki K. Control of cell selectivity of antimicrobial peptides. *Biochim Biophys Acta.* 2009;1788(8):1687–1692. doi:10.1016/j.bbame.2008.09.013
4. Huan Y, Kong Q, Mou H, Yi H. Antimicrobial peptides: classification, design, application and research progress in multiple fields. *Front Microbiol.* 2020;11:1–21. doi:10.3389/fmicb.2020.582779
5. Blancas-Luciano BE, Zamora-Chimal J, da Silva-de Rosenzweig PG, Ramos-Mares M, Fernández-Presas AM. Macrophages immunomodulation induced by *Porphyromonas gingivalis* and oral antimicrobial peptides. *Odontology.* 2023. doi:10.1007/s10266-023-00798-w

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Drug Design, Development and Therapy 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Drug Design, Development and Therapy editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Drug Design, Development and Therapy

Dovepress

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>

<https://doi.org/10.2147/DDDT.S415574>